Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
South Korea will invest 520 billion won in biotechnology next year to boost its development of treatment and vaccines for COVID-19.
The Ministry of Science and ICT said the figure represents a 24.9 percent hike from 2020.
Of that amount, 31.7 billion won will go to COVID-19 treatment and vaccine development and 10.2 billion won for technology to respond to new infectious diseases.
Some of it will also go to research into new core biotech industries, such as 71 billion won to develop a new medicine, 61.8 billion won in medical devices, and 31.1 billion won in regenerative medicine to strengthen research in stem cell technology and others.
The medical devices to be developed targets the elderly and the disabled.
The ministry said it also plans to invest 51.3 billion won to acquire next-generation biotech, such as single-cell analysis.
Last month, 36 South Korean biotech and pharmaceutical companies announced that they invest a combined 10 trillion won by 2023 to hone their competitiveness and technological capabilities.
The firms include Samsung Biologics Co. and Celltrion Inc., will
The government intends to spend a total of 2.2 trillion won on developing new medicine until 2030.
